
Palisade Bio, Inc. (NASDAQ:PALI – Free Report) – Research analysts at Brookline Capital Markets dropped their FY2026 earnings per share estimates for shares of Palisade Bio in a research report issued on Wednesday, November 11th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings per share of ($0.24) for the year, down from their prior estimate of ($0.21). The consensus estimate for Palisade Bio’s current full-year earnings is ($0.24) per share. Brookline Capital Markets also issued estimates for Palisade Bio’s Q4 2026 earnings at ($0.07) EPS, FY2027 earnings at ($0.29) EPS, FY2028 earnings at ($0.35) EPS, FY2029 earnings at ($0.48) EPS and FY2030 earnings at $0.44 EPS.
Palisade Bio (NASDAQ:PALI – Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.01).
Other equities analysts have also issued reports about the stock. Raymond James Financial started coverage on shares of Palisade Bio in a research report on Thursday, October 8th. They set an “outperform” rating and a $6.00 price target on the stock. HC Wainwright cut their price objective on shares of Palisade Bio to $5.00 and set a “buy” rating for the company in a report on Wednesday, November 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a research note on Monday, October 12th. Wall Street Zen lowered shares of Palisade Bio from a “sell” rating to a “strong sell” rating in a research note on Saturday. Finally, Oppenheimer restated an “outperform” rating on shares of Palisade Bio in a report on Wednesday, October 21st. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $9.00.
Read Our Latest Analysis on Palisade Bio
Palisade Bio Trading Down 8.0%
NASDAQ:PALI opened at $1.03 on Monday. The company’s 50-day moving average price is $1.46 and its 200-day moving average price is $1.81. The company has a market cap of $184.66 million, a P/E ratio of -2.15 and a beta of 1.61. Palisade Bio has a twelve month low of $1.01 and a twelve month high of $2.85.
Institutional Trading of Palisade Bio
A number of hedge funds and other institutional investors have recently modified their holdings of PALI. BlackRock Inc. purchased a new position in Palisade Bio during the second quarter worth about $21,813,000. Bank of New York Mellon Corp purchased a new stake in shares of Palisade Bio in the 2nd quarter valued at approximately $728,000. Wellington Management Group LLP grew its stake in shares of Palisade Bio by 27.5% in the 2nd quarter. Wellington Management Group LLP now owns 3,703,936 shares of the company’s stock valued at $7,741,000 after buying an additional 799,025 shares during the period. Octagon Capital Advisors LP grew its stake in shares of Palisade Bio by 7.4% in the 1st quarter. Octagon Capital Advisors LP now owns 10,276,317 shares of the company’s stock valued at $17,984,000 after buying an additional 708,419 shares during the period. Finally, Jupiter Topco LLC purchased a new stake in shares of Palisade Bio in the 2nd quarter valued at approximately $22,394,000. 11.79% of the stock is owned by institutional investors and hedge funds.
Palisade Bio Company Profile
Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.
Recommended Stories
- Five stocks we like better than Palisade Bio
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
